Richard Staines reviews the emergence of autotaxin (ATX) inhibition as a transformative approach in oncology, with the potential to expand into other diseases, including liver malignancies. Autotaxin (ATX) inhibition is emerging as a promising therapeutic strategy in oncology, with potential relevance to chronic liver disease and beyond. Although early trials in idiopathic pulmonary fibrosis (IPF)… Read More
Innovent Biologics revealed clinical data on two of its mAb (monoclonal antibody) programmes at the 2024 ESMO Congress. In a Phase I/II study in advanced solid tumours, IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) has demonstrated an excellent safety profile. A total of 368 participants… Read More
The European Society for Medical Oncology (ESMO) Congress 2024 took place in Barcelona, Spain, 13-17 September 2024, and featured some significant breakthroughs in cancer drug discovery. NIAGARA Phase III trial AstraZeneca presented positive results from its NIAGARA Phase III trial, a global study to evaluate the… Read More
Redx Pharma has announced data from all Phase II clinical trial modules of zamaporvint (RXC004), a potent, selective, orally-active Porcupine inhibitor in development for Wnt-ligand dependent, hard-to-treat gastrointestinal (GI) cancers. These data, presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress, were from… Read More
DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. Rausch gave an update on the latest developments… Read More
A novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) exhibited robust anti-tumour activity in humanised mouse models of colorectal cancer at low doses, according to data presented at the ESMO Immuno-Oncology (IO) Annual Congress. “We are thrilled to be presenting promising preclinical data on our novel multi-specific… Read More
The European Society for Medical Oncology Meeting (ESMO) 2023 took place from 20-24 October in Madrid, Spain. Many drug discovery companies took the opportunity to share their latest cancer research findings. Axicabtagene ciloleucel, Kite Two indirect comparative analyses of CAR T-cell therapy axicabtagene ciloleucel vs. bispecific… Read More
Ayala Pharmaceuticals has revealed positive interim results from its ongoing RINGSIDE Pivotal Phase II and III clinical trial into gamma-secretase inhibitor AL102 in desmoid tumours. The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2022 by Professor Robin Jones, MD, Head of the Sarcoma Unit at… Read More
